Testosterone Screening Could Bring Substantial Follow-Up, JAMA Analysis Finds

On October 15, 2026, JAMA published a research letter estimating how often healthy active-duty men aged 19 to 39 had testosterone readings below commonly used cutoffs. The researchers warned that routine screening would send many service members for repeat testing and clinical evaluation.

The researchers analyzed military screening measurements

According to the JAMA media release, the research focused on below-threshold testosterone measurements among healthy active-duty men. Its purpose was to estimate how often a screening result would fall below the lower limit used for comparison.

The authors used data from the Military Health and Nutrition Examination study. Military Times reported that data collection took place at five Army installations between August 2024 and January 2026.

That period describes the data collection window. This was an analysis of hormone measurements rather than a trial in which researchers assigned testosterone treatment and tracked its effects over time.

The participants’ ages and active-duty status define the population behind the findings. For a publication focused on men after 45, that distinction deserves attention before the results are applied to questions about midlife energy or recovery.

Military Times reported that the analysis examined a single morning testosterone reading against a cutoff of 300 ng/dL. The article used that threshold for comparison with American Urological Association guidance.

Many single readings fell below the comparison cutoff

The main physiological finding was the estimated frequency of testosterone measurements below 300 ng/dL. Military Times reported these results:

• The analysis estimated that 100,691 active-duty soldiers had a single morning testosterone result below 300 ng/dL.
• Among male soldiers younger than 30, the estimated share below that cutoff was 20%.
• Among those aged 30 or older, the estimated share was 32.8%.

The age breakdown needs its full context. The group described as 30 or older was part of an analysis involving healthy active-duty men aged 19 to 39. It was not a separate sample of men in later life.

These figures explain why the researchers focused on what happens after screening. A program that identifies many below-threshold results also needs a way to interpret those results and arrange appropriate follow-up.

The reported total is an estimate from the analysis. It should not be read as the number of participants enrolled in the underlying study or as a count of men who started treatment.

Screening policy makes follow-up capacity a central question

Military Times placed the analysis within a Department of Defense screening initiative. The program calls for screening male service members aged 30 and older. Screening is voluntary for younger personnel who request it and have symptoms.

The distinction between screening policy and clinical evidence matters here. A policy determines who is offered a test. Clinical evaluation determines what a result means for the person tested.

According to Military Times, Defense Health Agency guidelines call for morning testing on two separate days. Results below 300 ng/dL may prompt further evaluation. Treatment is not mandatory.

The JAMA researchers wrote that routine screening “will result in confirmatory testing and clinical evaluation for many male service members.” They described a positive screening result as a potential starting point for repeat testing and further assessment. Counseling about modifiable factors and consideration of treatment may follow when indicated.

That makes follow-up part of the screening question rather than a minor administrative detail. The initial blood test is only the first service a screening program may need to provide. Repeat measurements, medical visits and counseling also require time and resources.

The authors therefore raised concerns about additional visits, costs and treatment that broad screening could generate. Their focus was the possible demand created by the program, not simply how many laboratory values fell below a line.

Treatment findings require a separate discussion

The Military Times coverage also reviewed treatment benefits and potential harms. Those findings came from other evidence cited in the article, not from treatment outcomes measured in the new JAMA analysis.

The article described a 2018 NIH study of 800 older men. It reported improvements in erectile dysfunction, libido and mood with testosterone therapy. It also reported little or no improvement in fatigue, memory or overall well-being.

Those outcomes deserve to remain separate rather than being grouped under a broad promise of feeling younger. A benefit for sexual function is not the same outcome as a benefit for fatigue. An improvement in mood does not establish an improvement in memory.

That distinction is especially relevant when weighing claims that testosterone is a broad fix. A useful discussion identifies the concern being addressed and asks which reported outcomes match that concern.

Military Times also reported potential adverse effects of treatment:

• Blood clots.
• Reduced sperm count, which can cause infertility.
• Possible mood effects, including irritability and aggression.

These are potential harms to discuss, not outcomes that occur in every person receiving treatment. The researchers stressed the need for careful clinical interpretation because testosterone replacement is long term and has possible adverse effects.

For men with fertility goals, the reported effect on sperm production is a specific issue to raise before considering treatment. The decision involves more than whether a laboratory value crosses a cutoff.

The analysis leaves important clinical questions open

The study has several boundaries that shape its meaning:

• A low screening result is not a diagnosis. The researchers explicitly cautioned that an isolated low measurement does not establish hypogonadism. Symptoms and clinical evaluation remain part of the distinction between a laboratory finding and a clinical condition.
• The population does not represent all older men. Findings from healthy active-duty men aged 19 to 39 should not be used to estimate the prevalence of testosterone deficiency among men after 45.
• Projected follow-up is not demonstrated harm. The analysis did not show that routine screening had already caused unnecessary treatment, worse health outcomes or a measured increase in medical costs.

These boundaries do not remove the study’s value. They locate it: the research helps assess the scale of possible screening-related care. It does not settle whether a particular person should be tested or treated.

The practical question is therefore narrower than whether testosterone screening is good or bad for everyone. It is how a screening program connects an initial result with an appropriate clinical decision.

Persistent symptoms deserve a clinical conversation

For men over 45 concerned about energy, strength, mood or sexual health, the useful next step is to discuss persistent symptoms and any existing test results with a qualified clinician. Personal decisions about testing and treatment need that clinical context.

The military protocol is useful background for understanding why repeat measurements appear in the discussion. It is not a self-directed testing schedule for the general public.

A focused conversation can address several questions without assuming the answer in advance:

• How do the symptoms and test result fit together?
• What further evaluation is appropriate before a diagnosis is made?
• Which concern would treatment be intended to address?
• What benefits and adverse effects matter to that decision?
• Are fertility goals relevant to the choice?

This keeps the discussion tied to a person’s actual concern. If fatigue is the main issue, evidence about sexual function should not stand in for evidence about fatigue. If fertility matters, that priority belongs in the conversation before treatment decisions are made.

The researchers’ warning also gives screening programs a clear responsibility: the pathway after a low result deserves as much attention as the test itself. Identifying an abnormal value and providing useful care are connected tasks, but they are not interchangeable.

What this changes: The study adds context on the potential demand for follow-up, but it reinforces existing clinical evaluation rather than establishing a new treatment standard for men over 45.

How Everfitguys helps

A testosterone number can become a misleading explanation for poor sleep or slow recovery when clinical context drops out, a shortcut Everfitguys avoids through research-led writing. Its plain-language coverage helps men 45 and older understand hormone claims alongside concerns about stress and falling energy, with staying capable as the focus rather than a promised treatment outcome.

Read the research

Sources

1. Routine testosterone screening of US troops may require ...
2. Testosterone Screening Thresholds in Active-Duty US Male ...